Every 8-K that NewAmsterdam Pharma Company N.V. Warrant (NAMSW) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow NAMSW and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full NAMSW filings page.
NewAmsterdam Pharma Company N.V. filed an amendment detailing the final terms of separation and advisory agreements with former Chief Operating Officer Douglas Kling, who resigned effective August 14, 2026 to become chief executive officer of another clinical-stage biotech company. Under a letter separation agreement with a subsidiary, Kling’s unvested stock options and restricted stock units as of the separation date are canceled, except for portions that vest solely based on continued service through May 14, 2027, which may continue to vest while he serves as an advisor. The agreement also includes confidentiality, non-disparagement, non-solicitation covenants, and a release of claims. A separate advisor agreement with another subsidiary provides that Kling will deliver transition and advisory services related to the PREVAIL clinical trial of obicetrapib and other programs for a $50,000 monthly service fee plus reimbursable expenses, through May 14, 2027 unless terminated earlier.
NewAmsterdam Pharma Company N.V. appointed Robert W. Gunning, 55, as principal accounting officer effective August 10, 2026, succeeding Louise Kooij, whose departure effective August 31, 2026 had been previously announced. Gunning joined as Vice President, Controller on the same date, bringing prior senior finance and controller experience at several biopharmaceutical and biotechnology companies.
Under a July 24, 2026 offer letter with a wholly owned subsidiary, Gunning will receive a $375,000 annual base salary and be eligible for an annual performance bonus targeted at 30% of base salary, prorated for his first year and subject to board discretion. He will also be granted 3,200 restricted stock units and a stock option to purchase 14,000 ordinary shares under the 2024 Inducement Plan. The company states he has no disclosable related-party relationships or material interests in company transactions beyond standard indemnification arrangements.
NewAmsterdam Pharma Company N.V. reported results for the quarter ended June 30, 2026 and highlighted regulatory and clinical developments. The Committee for Medicinal Products for Human Use issued a positive opinion recommending EU marketing authorization for obicetrapib (Ubeslo) and the obicetrapib/ezetimibe fixed-dose combination (Evlarco), with a European Commission decision expected later this year.
The company is running multiple Phase 3 programs, including the PREVAIL cardiovascular outcomes trial with over 9,500 patients enrolled and an interim analysis planned for the fourth quarter of 2026, the REMBRANDT imaging trial with 323 patients enrolled, and the RUBENS diabetes/metabolic syndrome trial targeting about 300 patients and topline data by year-end 2026. Cash, cash equivalents and marketable securities were $678.3 million at June 30, 2026. Revenue for the three months ended June 30, 2026 was $3.7 million versus $19.1 million a year earlier, reflecting lower contributions under the Menarini license and supply arrangements. R&D expenses rose to $41.7 million, SG&A expenses were $26.9 million, and net loss widened to $64.1 million compared with $17.4 million in the prior-year period.
NewAmsterdam Pharma Company N.V. reports that the EMA’s Committee for Medicinal Products for Human Use issued a positive opinion recommending marketing authorization for Ubeslo (obicetrapib 10 mg monotherapy) and Evlarco (10 mg obicetrapib plus 10 mg ezetimibe) to treat primary hypercholesterolemia, including heterozygous familial and non-familial or mixed dyslipidemia.
The recommendation is based on Phase 3 BROADWAY, BROOKLYN and TANDEM trials, which showed LDL-C reductions up to 40% with obicetrapib alone and approximately 50% in combination with ezetimibe versus placebo, with tolerability comparable to placebo. A European Commission decision, which could grant centralized EU marketing authorization, is expected in the second half of 2026.
Under a licensing agreement, Menarini holds exclusive European commercialization rights and is responsible for regulatory and commercial activities, while NewAmsterdam is eligible for tiered double-digit royalties and up to €833 million in additional milestones, and continues to run the over 9,500-patient PREVAIL cardiovascular outcomes trial.
NewAmsterdam Pharma Company N.V. announced that Chief Operating Officer Douglas Kling notified the company on July 16, 2026 that he will resign, with his departure effective August 14, 2026. He is leaving to become chief executive officer of another clinical-stage biotech company.
The company expects to enter into a separation agreement with Mr. Kling and an advisor agreement under which he would provide transition and advisory services for the PREVAIL clinical trial of obicetrapib and other clinical programs. Material terms of these agreements are expected to be disclosed later.
NewAmsterdam Pharma Company N.V. reported results of its 2026 annual general meeting, where shareholders approved a new 2026 Employee Stock Purchase Plan (ESPP) and several governance items. The ESPP allows eligible employees to buy ordinary shares using payroll deductions at a 15% discount to the lower market price at the start or end of each six‑month purchase period.
The aggregate number of ordinary shares that may be issued under the ESPP is capped at 1,150,000, and the plan will terminate on June 2, 2036 unless ended earlier by the board. Shareholders also approved the 2025 statutory accounts, discharged directors from liability for 2025, reappointed Deloitte Accountants B.V. as auditor, reappointed two non‑executive directors, extended authorizations for share issuance and pre‑emption rights limitations through June 2, 2031, and passed a non‑binding say‑on‑pay vote for 2025 compensation.
NewAmsterdam Pharma reported first quarter 2026 results and a broad clinical update. Revenue was $3.0 million, while net loss widened to $48.4 million from $39.5 million a year earlier. Cash, cash equivalents and marketable securities totaled $707.3 million as of March 31, 2026.
The company highlighted ongoing Phase 3 programs for obicetrapib, including the PREVAIL cardiovascular outcomes trial with over 9,500 patients enrolled, REMBRANDT with 323 patients enrolled, and RUBENS targeting about 300 patients. Interim PREVAIL analysis is planned for 4Q 2026 with results expected in 1Q 2027.
Regulatory decisions in Europe, the UK and Switzerland for obicetrapib and the obicetrapib/ezetimibe fixed‑dose combination are expected in 2H 2026, with potential launches by Menarini in 4Q 2026 in Germany and the UK. The company also described Alzheimer’s biomarker findings from the BROADWAY trial and plans a new trial in early Alzheimer’s disease in 2026.
NewAmsterdam Pharma Company N.V. reports that Chief Accounting Officer Louise Kooij will end her employment effective August 31, 2026. The company and Ms. Kooij entered into a separation agreement on April 24, 2026.
Under this agreement, she is eligible for a lump-sum payment equal to twelve months of her current base salary, a pro-rated 2026 annual cash bonus based on target achievement through the separation date, and payment for accrued but unused holiday and vacation days in line with Dutch law.
The company will extend vesting of her outstanding stock options and RSU awards through January 10, 2027, and vested stock options will remain exercisable until February 10, 2027. The agreement also includes confidentiality, non-compete and non-disparagement covenants and a release of claims, and is expected to be filed with the company’s Form 10-Q for the quarter ending June 30, 2026.
NewAmsterdam Pharma Company N.V. furnished an updated investor presentation that highlights the development and commercialization plans for its CETP inhibitor obicetrapib.
The company describes obicetrapib as a once-daily oral therapy that produced LDL-C reductions of about 35–40% as monotherapy and roughly 50–60% when combined with ezetimibe across multiple Phase 2 and Phase 3 trials, with additional ~45% Lp(a) lowering versus placebo in pooled analyses. Exploratory analyses from the Phase 3 BROADWAY trial showed an observed 21% reduction in major adverse cardiovascular events at one year versus placebo, with pooled BROADWAY and BROOKLYN data also favoring obicetrapib, while noting these studies were not powered for outcomes.
The presentation outlines a potential global peak sales opportunity of more than $8 billion for cardiometabolic use, citing over 30 million U.S. patients on lipid-lowering drugs who are not at LDL-C goal. It also reports cash, cash equivalents and marketable securities of approximately $729 million at year-end 2025, intended to support a prospective U.S. launch if approved. Additional data show a 2.84% treatment benefit on p‑tau217 progression overall and a 20.5% benefit in ApoE4 homozygotes over 12 months, along with favorable changes in other Alzheimer’s biomarkers. The company emphasizes intellectual property protection, including composition-of-matter coverage extending into 2043, and a broad late-stage clinical program, including the PREVAIL cardiovascular outcomes trial and multiple Phase 3 and Phase 2 studies.
NewAmsterdam Pharma reported full year 2025 results and highlighted progress advancing its cholesterol drug obicetrapib. Revenue was $22.5 million, down from $45.6 million in 2024, while the net loss narrowed to $203.8 million from $241.6 million as R&D expenses declined.
Cash, cash equivalents and marketable securities totaled $728.9 million at December 31, 2025, which the company expects will fund operations through the PREVAIL cardiovascular outcomes readout and, if approved, support a potential U.S. launch. Marketing applications for obicetrapib and a fixed-dose combination with ezetimibe have been accepted in Europe, the UK and Switzerland, with decisions anticipated in the second half of 2026.
The company is running three Phase 3 trials—PREVAIL, REMBRANDT and RUBENS—and plans to start a trial of obicetrapib in early Alzheimer’s disease in 2026 following positive Alzheimer’s biomarker data from the BROADWAY study.
NewAmsterdam Pharma Company N.V. furnished a current report to let the market know it has posted an updated corporate investor presentation on its website as of September 2, 2025. The presentation, dated the same day, is attached as Exhibit 99.1 and provides investors with the latest corporate information in slide format. The company emphasizes that this material is furnished under Regulation FD, not filed, meaning it is not subject to certain securities law liabilities and is not automatically incorporated into any of its existing or future registration statements or Exchange Act filings unless expressly stated.
NewAmsterdam Pharma Company N.V. reports that the European Medicines Agency has validated its Marketing Authorization Application for obicetrapib 10 mg as monotherapy and for a 10 mg obicetrapib plus 10 mg ezetimibe fixed-dose combination. These treatments are aimed at patients with primary hypercholesterolemia, including both heterozygous familial and non-familial cases, as well as mixed dyslipidemia.
The validation allows the EMA to begin substantive review of data from the Company’s BROADWAY, BROOKLYN and other Phase 3 clinical trials. The MAA was submitted by A. Menarini International Licensing S.A., which holds an exclusive license with a NewAmsterdam subsidiary and is responsible for European regulatory interactions, commercialization, local development of obicetrapib, and related collaborative activities.
NewAmsterdam Pharma Company N.V. disclosed that its subsidiary, NewAmsterdam Pharma B.V., entered into a Supply Agreement with A. Menarini International Licensing S.A. on August 12, 2025. Under this agreement, the subsidiary will initially act as Menarini’s exclusive supplier of obicetrapib monotherapy and an obicetrapib/ezetimibe fixed-dose combination in bulk tablet form. Menarini must provide periodic volume forecasts, part of which will be binding, and pricing will be based on a defined mark-up over the subsidiary’s cost of goods sold, with periodic adjustments.
The parties will also start a process to transfer manufacturing of these drug products to Menarini or a designated third-party manufacturer. To support that transfer, NewAmsterdam’s subsidiary granted Menarini a non-exclusive, non-transferable license under the company’s patents and know-how to manufacture finished drug products. The Supply Agreement runs for the duration of the existing License Agreement, with rights for early termination in specified cases such as convenience (subject to timing conditions), uncured material breach, insolvency, or extended force majeure.
NewAmsterdam Pharma (NAMS/NAMSW) furnished an 8-K to disclose full Alzheimer’s disease (AD) biomarker data from the prespecified analysis of its Phase 3 BROADWAY LDL-C trial evaluating CETP inhibitor obicetrapib. In 1,727 patients (367 ApoE4 carriers) treated 12 months with 10 mg daily, obicetrapib produced a -2.99 % mean change in plasma p-tau217 vs. placebo (p = 0.019); effects intensified in genetic and age subgroups, reaching -20.48 % in ApoE4/E4 carriers (n = 29; p = 0.010). Statistically significant or favorable trends were also observed for NFL, GFAP, p-tau181 and Aβ42/40, biomarkers linked to neurodegeneration.
Safety was not analyzed separately but was stated to mirror the overall BROADWAY population, where obicetrapib was well-tolerated and comparable to placebo. The exploratory AD analysis was not adjusted for baseline differences. Results will be presented 30 July 2025 at AAIC; a company webcast will follow at 10:00 a.m. ET. Exhibits 99.1 (press release) and 99.2 (presentation) are furnished, with no financial statements included.